These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1783916)

  • 1. Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation.
    Ricciardi R; Rossi B; Nicora M; Sghirlanzoni A; Muratorio A
    J Neurol Neurosurg Psychiatry; 1991 Dec; 54(12):1061-2. PubMed ID: 1783916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal versus intravenous neostigmine in myasthenia gravis: assessment by computer analysis of saccadic eye movements.
    Di Costanzo A; Toriello A; Mannara C; Benvenuti C; Tedeschi G
    Clin Neuropharmacol; 1993 Dec; 16(6):511-7. PubMed ID: 9377586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of intranasal administration of neostigmine in myasthenic patients.
    Sghirlanzoni A; Pareyson D; Benvenuti C; Cei G; Cosi V; Lombardi M; Nicora M; Ricciardi R; Cornelio F
    J Neurol; 1992 Mar; 239(3):165-9. PubMed ID: 1573422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylcholinesterase inhibitor treatment for myasthenia gravis.
    Mehndiratta MM; Pandey S; Kuntzer T
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006986. PubMed ID: 25310725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of neostigmine on the electromyographic record in myasthenia].
    Wochnik-Dyjas D; Niewiadomska M
    Neurol Neurochir Pol; 1970; 4(1):7-13. PubMed ID: 5439405
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and CN-SFEMG evaluation of neostigmine test in myasthenia gravis.
    Sciacca G; Reggio E; Mostile G; Nicoletti A; Drago F; Salomone S; Zappia M
    Neurol Sci; 2018 Feb; 39(2):341-345. PubMed ID: 29330628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous neostigmine in the management of severe myasthenia gravis.
    Bingle JP; Rutherford JD; Woodrow P
    Br Med J; 1979 Apr; 1(6170):1050. PubMed ID: 444916
    [No Abstract]   [Full Text] [Related]  

  • 8. Myasthenia gravis with features of the myasthenic syndrome. An investigation with electrophysiologic methods including single-fiber electromyography.
    Schwartz MS; Stålberg E
    Neurology; 1975 Jan; 25(1):80-4. PubMed ID: 1167410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of prostigmin on the basal electromyogram in myasthenia.
    Wochnik-Dyjas D; Niewiadomska M
    Pol Med J; 1970; 9(4):932-8. PubMed ID: 4320112
    [No Abstract]   [Full Text] [Related]  

  • 10. Neostigmine-responsive weakness in the dog, similar to myasthenia gravis.
    Lorenz MD; DeLahunta A; Alstrom DH
    J Am Vet Med Assoc; 1972 Oct; 161(7):795-800. PubMed ID: 5074261
    [No Abstract]   [Full Text] [Related]  

  • 11. Acetylcholinesterase inhibitor treatment for myasthenia gravis.
    Mehndiratta MM; Pandey S; Kuntzer T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006986. PubMed ID: 21328290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [On the treatment of myasthenia].
    Delwaide JP
    Rev Med Liege; 1968 Sep; 23(18):552-7. PubMed ID: 4316587
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapetic measures in myasthenia gravis].
    Cavaciuti P; Gatti E
    Minerva Anestesiol; 1969 Aug; 35(8):765-79. PubMed ID: 5364124
    [No Abstract]   [Full Text] [Related]  

  • 14. [Electrocardiographic changes in myasthenia gravis].
    Lurie B; Kott E; Freud M
    Harefuah; 1969 Nov; 77(10):455-6. PubMed ID: 5397702
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral neostigmine and lymphatic absorption in a myasthenia gravis patient on continuous ambulatory peritoneal dialysis (CAPD).
    Chan PC; Tam SC; Cheng IK
    Perit Dial Int; 1990; 10(1):93-6. PubMed ID: 2085592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of subacute administration of discrete doses of ACTH in medium grade myasthenia. (Serial electromyographic study)].
    Pinelli P
    Riv Neurol; 1967; 37(4):343-65. PubMed ID: 4295653
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of corticosteroids in a dog with myasthenia gravis.
    Van Heerden J; Van Schouwenburg SJ
    J S Afr Vet Assoc; 1983 Jun; 54(2):135-7. PubMed ID: 6631903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administering Neostigmine as a Subcutaneous Infusion: A Case Report of a Patient Dying With Myasthenia Gravis.
    Hindmarsh J; Woods E; Lee M; Pickard J
    J Palliat Care; 2020 Apr; 35(2):78-81. PubMed ID: 31411109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myasthenia gravis associated with diphenylhydantoin therapy for epilepsy.
    Brumlik J; Jacobs RS
    Can J Neurol Sci; 1974 May; 1(2):127-9. PubMed ID: 4215556
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
    Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO; Stålberg E
    J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):929-35. PubMed ID: 6644317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.